216 related articles for article (PubMed ID: 8769587)
1. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial.
Borhani NO; Mercuri M; Borhani PA; Buckalew VM; Canossa-Terris M; Carr AA; Kappagoda T; Rocco MV; Schnaper HW; Sowers JR; Bond MG
JAMA; 1996 Sep; 276(10):785-91. PubMed ID: 8769587
[TBL] [Abstract][Full Text] [Related]
2. MIDAS: rationale, design and descriptive data of trial patients. The MIDAS Research Group.
Borhani NO
Blood Press Suppl; 1994; 1():29-35. PubMed ID: 8205295
[TBL] [Abstract][Full Text] [Related]
3. MIDAS, the Multicenter Isradipine/Diuretic Atherosclerosis Study. Design features and baseline data.
Applegate WB; Byington RP
Am J Hypertens; 1991 Feb; 4(2 Pt 2):114S-117S. PubMed ID: 1827000
[TBL] [Abstract][Full Text] [Related]
4. Calcium antagonists and atherosclerosis. The Multicenter Isradipine/Diuretic Atherosclerosis Study.
Furberg CD; Borhani NO; Byington RP; Gibbons ME; Sowers JR
Am J Hypertens; 1993 Mar; 6(3 Pt 2):24S-29S. PubMed ID: 8466723
[TBL] [Abstract][Full Text] [Related]
5. Vascular events during antihypertensive treatment.
Madren EM
J Fam Pract; 1996 Dec; 43(6):534. PubMed ID: 8969693
[No Abstract] [Full Text] [Related]
6. The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS).
Kaufman JL
JAMA; 1997 Jan 22-29; 277(4):297; author reply 297-8. PubMed ID: 9002486
[No Abstract] [Full Text] [Related]
7. Hydrochlorothiazide is superior to isradipine for reduction of left ventricular mass: results of a multicenter trial. The Isradipine Study Group.
Papademetriou V; Gottdiener JS; Narayan P; Cushman WG; Zachariah PK; Gottdiener PS; Chase GA
J Am Coll Cardiol; 1997 Dec; 30(7):1802-8. PubMed ID: 9385910
[TBL] [Abstract][Full Text] [Related]
8. The antiatherosclerotic effect of calcium antagonists in man--what did MIDAS actually show? Multicenter Isradipine Diuretic Atherosclerosis Study.
Hansson L; Zanchetti A
Blood Press; 1995 May; 4(3):133-6. PubMed ID: 7670645
[TBL] [Abstract][Full Text] [Related]
9. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.
Black HR; Elliott WJ; Grandits G; Grambsch P; Lucente T; White WB; Neaton JD; Grimm RH; Hansson L; Lacourciere Y; Muller J; Sleight P; Weber MA; Williams G; Wittes J; Zanchetti A; Anders RJ;
JAMA; 2003 Apr 23-30; 289(16):2073-82. PubMed ID: 12709465
[TBL] [Abstract][Full Text] [Related]
10. A comparison of antihypertensive drug effects on the progression of extracranial carotid atherosclerosis. The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS).
Grimm RH; Flack JM; Byington R; Bond G; Brugger S
Drugs; 1990; 40 Suppl 2():38-43. PubMed ID: 2150640
[TBL] [Abstract][Full Text] [Related]
11. Felodipine extended release versus conventional diuretic therapy for the treatment of systolic hypertension in elderly patients. The National Trial Group.
McClennen W; Wilson T
Clin Invest Med; 1998 Jun; 21(3):142-50. PubMed ID: 9627768
[TBL] [Abstract][Full Text] [Related]
12. The Multicenter Isradipine/Diuretic Atherosclerosis Study: a study of the antiatherogenic properties of isradipine in hypertensive patients. MIDAS Research Group.
Borhani NO; Bond MG; Sowers JR; Canossa-Terris M; Buckalew V; Gibbons ME; Worthy AJ
J Cardiovasc Pharmacol; 1991; 18 Suppl 3():S15-9. PubMed ID: 1720479
[TBL] [Abstract][Full Text] [Related]
13. MIDAS: hypertension and atherosclerosis. A trial of the effects of antihypertensive drug treatment on atherosclerosis. MIDAS Research Group.
Borhani NO; Miller ST; Brugger SB; Schnaper HW; Craven TE; Bond MG; Khoury S; Flack J
J Cardiovasc Pharmacol; 1992; 19 Suppl 3():S16-20. PubMed ID: 1376828
[TBL] [Abstract][Full Text] [Related]
14. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.
Pepine CJ; Handberg EM; Cooper-DeHoff RM; Marks RG; Kowey P; Messerli FH; Mancia G; Cangiano JL; Garcia-Barreto D; Keltai M; Erdine S; Bristol HA; Kolb HR; Bakris GL; Cohen JD; Parmley WW;
JAMA; 2003 Dec; 290(21):2805-16. PubMed ID: 14657064
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
[TBL] [Abstract][Full Text] [Related]
16. Effect of antihypertensive treatment on cardiac and subcutaneous artery structure: a comparison between calcium channel blocker and thiazide-based regimens.
Sihm I; Schroeder AP; Aalkjaer C; Mulvany MJ; Thygesen K; Lederballe O
Am J Hypertens; 1998 Mar; 11(3 Pt 1):263-71. PubMed ID: 9544865
[TBL] [Abstract][Full Text] [Related]
17. Multicenter study with isradipine and diuretics against atherosclerosis. US MIDAS Research Group.
Borhani NO; Brugger SB; Byington RP
J Cardiovasc Pharmacol; 1990; 15 Suppl 1():S23-9. PubMed ID: 1695298
[TBL] [Abstract][Full Text] [Related]
18. Little effect of ordinary antihypertensive therapy on nocturnal high blood pressure in patients with sleep disordered breathing.
Pelttari LH; Hietanen EK; Salo TT; Kataja MJ; Kantola IM
Am J Hypertens; 1998 Mar; 11(3 Pt 1):272-9. PubMed ID: 9544866
[TBL] [Abstract][Full Text] [Related]
19. Doxazosin and hydrochlorothiazide equally affect arterial wall thickness in hypertensive males with hypercholesterolaemia (the DAPHNE study). Doxazosin Atherosclerosis Progression Study in Hypertensives in the Netherlands.
Hoogerbrugge N; de Groot E; de Heide LH; de Ridder MA; Birkenhägeri JC; Stijnen T; Jansen H
Neth J Med; 2002 Oct; 60(9):354-61. PubMed ID: 12572707
[TBL] [Abstract][Full Text] [Related]
20. Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials.
Lacourcière Y; Neutel JM; Schumacher H
Clin Ther; 2005 Nov; 27(11):1795-805. PubMed ID: 16368450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
